T0	Outcomes 1280 1314	attain blood trough concentrations
T1	Outcomes 2063 2080	reduction in SEGA
T2	Outcomes 2096 2123	39·0-58·3), and duration of
T3	Outcomes 2173 2186	not reached).
T4	Outcomes 2370 2383	at 144 weeks.
T5	Outcomes 2405 2424	patients) and mouth
T6	Outcomes 2497 2512	adverse events;
T7	Outcomes 2674 2694	grade 3 or 4 adverse
T8	Outcomes 2719 2732	of which were
T9	Outcomes 2744 2759	(nine [8%]) and
T10	Outcomes 2792 2838	patients had treatment-related serious adverse
T11	Outcomes 2865 2892	withdrew because of adverse
T12	Outcomes 3094 3109	manifestations.
T13	Outcomes 3110 3146	Reduction or stabilisation of tumour